Improved cationic lipid formulations for in vivo gene therapy.
about
Liposome-mediated delivery of antiviral agents to human immunodeficiency virus-infected cells.In vivo gene delivery by cationic tetraamino fullerene.Enhanced gene transfer with fusogenic liposomes containing vesicular stomatitis virus G glycoprotein.Gene delivery to the spinal cord: comparison between lentiviral, adenoviral, and retroviral vector delivery systemsAnticytokine gene therapy of autoimmune diseases.Gene transfer of human hepatocyte growth factor into rat skin wounds mediated by liposomes coated with the sendai virus (hemagglutinating virus of Japan).Lipoplexes formed by DNA and ferrocenyl lipids: effect of lipid oxidation state on size, internal dynamics, and zeta-potential.Calcium phosphate nanoparticles: second-generation nonviral vectors in gene therapy.Aerosol Delivery of siRNA to the Lungs. Part 2: Nanocarrier-based Delivery SystemsGene therapy in wound healing: present status and future directions.Characterization of the nanostructure of complexes formed by a redox-active cationic lipid and DNAPolymers for DNA delivery.Nerve growth factor expression by PLG-mediated lipofection.A novel cationic lipid greatly enhances plasmid DNA delivery and expression in mouse lung.Polymersome delivery of siRNA and antisense oligonucleotides.The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methodsSolid lipid nanoparticles for applications in gene therapy: a review of the state of the art.Molecular basis of the mucosal immune system: from fundamental concepts to advances in liposome-based vaccines.Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy.Effect of lyophilization and freeze-thawing on the stability of siRNA-liposome complexes.Novel pH-sensitive cationic lipids with linear ortho ester linkers for gene delivery.Advanced materials for co-delivery of drugs and genes in cancer therapy.Polycation-induced cell membrane permeability does not enhance cellular uptake or expression efficiency of delivered DNA.Lipid-mediated delivery of RNA is more efficient than delivery of DNA in non-dividing cells.Targeted gene therapy of LS174 T human colon carcinoma by anti-TAG-72 immunoliposomes.Polyethylenimine-DNA solid particles for gene delivery.DNA internalized via caveolae requires microtubule-dependent, Rab7-independent transport to the late endocytic pathway for delivery to the nucleus.Formulation and in vitro transfection efficiency of poly (D, L-lactide-co-glycolide) microspheres containing plasmid DNA for gene deliveryEnhancement of polyethylene glycol (PEG)-modified cationic liposome-mediated gene deliveries: effects on serum stability and transfection efficiency.Combined delivery of temozolomide and the thymidine kinase gene for treatment of glioblastoma.Folate-targeted, cationic liposome-mediated gene transfer into disseminated peritoneal tumors.Intraperitoneal gene delivery mediated by a novel cationic liposome in a peritoneal disseminated ovarian cancer model.Influence of lipophilic groups in cationic alpha-helical peptides on their abilities to bind with DNA and deliver genes into cells.Achieving long-term stability of lipid nanoparticles: examining the effect of pH, temperature, and lyophilization.Metabolically stabilized long-circulating PEGylated polyacridine peptide polyplexes mediate hydrodynamically stimulated gene expression in liver.The covalent bioconjugate of multiwalled carbon nanotube and amino-modified linearized plasmid DNA for gene delivery.Lipoplex size determines lipofection efficiency with or without serum.Cationic lipid-mediated transfection of cells in culture requires mitotic activity.IGF-I gene transfer in thermally injured rats.Lipoplex size is a major determinant of in vitro lipofection efficiency.
P2860
Q33637970-353619B2-80EA-4862-B63E-B25F5769F4AEQ33777666-6D72E455-14B0-4C4C-AC39-4DEC76D535C5Q33785847-9C67821A-4237-47E4-88C6-14458BEF558FQ33821596-FB6D7769-F844-4BB5-B2B3-B91CB6AC1FB2Q34451949-5C8B9903-97A6-4B03-9376-1D16282B4767Q35747709-C04EAD05-A21B-4F3F-B7F5-ED825DEDBA17Q36175881-E8FCCCDC-EEE5-433C-BB52-240D3BD36A7FQ36299906-6B56A239-679C-45DF-B61F-743F37E02026Q36341433-629AF495-2F69-4AD7-AFFF-029F00026CF3Q36575417-2D2AF768-3153-4368-AF2D-C2EAF64F0A10Q36926088-BEC7D0AA-41BB-4165-807D-872D637BB81BQ37002661-FD3E2F20-6D8C-49E8-BC12-F2DE9DE29264Q37111523-19228E28-4600-4742-9E9D-29E7F2576230Q37253992-8ADE943B-FBA5-4E3B-BA59-CDD121C09611Q37338790-1A986DED-6A0B-437F-BA9D-057A1C486885Q37464882-5998B3E7-D4CE-4405-8645-65DBA63F2846Q37657507-F38D648C-8E78-4F32-8943-6F0D5DE3ECCFQ37818335-87F0C74C-F4BE-4C18-B575-C700A0476D3AQ38074442-F5E45372-DF32-457D-BEB7-2B53A03E9EECQ38291528-7F7BB699-C427-4DE3-9ADE-1331D910D193Q39368753-8A3C17C1-79D5-4CFB-9A56-AD8C5C8B9BD7Q39513734-B6F6A658-6F83-4640-AFEF-71BDE87FBA53Q39721514-2EAE6784-F6D3-41D5-AEF2-FE230C47F00CQ39904203-5E544999-D9BA-4816-80A6-AFADAF0FD992Q40007582-12345D93-86D6-4911-AE77-DEE106F39A67Q40044120-4BA9BB05-CEF0-4764-8EAC-FB1801A538A2Q40204575-608D41F7-8D01-4C5F-B1BD-41C2DC0B924FQ40598735-DE9FA103-C4E2-4B12-A64D-1A3728008251Q40640248-4F98F85C-F843-43D2-9C78-5D2B4175E0C3Q40657080-2C0D5B1E-AC1E-4749-A511-E53D27827C98Q40693497-E8660F62-7E6B-4EB9-AB37-7CC5BCD36232Q40722841-DD384C81-8682-4D85-8EB1-F325969E2B2BQ40921641-AEEAAAD4-FB57-4195-83CE-540D59A35A41Q41032094-D9A91865-6C82-4D88-A303-60F4D127868BQ41566501-B26BDDC2-D209-4030-9957-81949F3D476EQ43778012-B0599BA0-8AA3-4619-A467-53A611D2B654Q44440271-EA40A797-104F-4A1C-8C8E-5C351ED1DE81Q45859684-80761012-11D2-476F-9057-C4648FF9F5D4Q45861506-4042CB53-ECAD-4FFE-9F26-5B5C2EBE92ADQ45862148-5023CB16-5A14-4D99-91B9-5FBB0F826762
P2860
Improved cationic lipid formulations for in vivo gene therapy.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Improved cationic lipid formulations for in vivo gene therapy.
@en
type
label
Improved cationic lipid formulations for in vivo gene therapy.
@en
prefLabel
Improved cationic lipid formulations for in vivo gene therapy.
@en
P2093
P2860
P1476
Improved cationic lipid formulations for in vivo gene therapy.
@en
P2093
Felgner PL
Manthorpe M
Marshall J
Wheeler CJ
P2860
P304
P356
10.1111/J.1749-6632.1995.TB44738.X
P407
P577
1995-11-01T00:00:00Z